Literature DB >> 23730924

Pharmaceutical applications of the Calu-3 lung epithelia cell line.

Hui Xin Ong1, Daniela Traini, Paul M Young.   

Abstract

INTRODUCTION: The Calu-3 lung cell line has been shown to be a promising in vitro model of airway epithelia due to its similarity to in vivo physiology. Hence, over the past decade, it has found increasing applications in the pharmaceutical industry. AREAS COVERED: This review focuses on the pharmaceutical applications of the Calu-3 cell line in areas such as mechanisms of drug transport, studying aerosol deposition, controlled release studies and identification of possible drug-drug interactions. The main findings of various studies, as well as the predictive potential of this model, are presented and discussed in this review. EXPERT OPINION: There is still a lack of mechanistic knowledge regarding transport of inhaled therapeutics across the lungs. Cell culture models such as Calu-3 provide a simple and reproducible system to study the underlying mechanisms by which inhaled therapeutics interact with the lungs. However, more complex systems that integrate particle deposition onto different cell culture systems may be useful in addressing some fundamental questions to generate a better understanding of determinants that influences pulmonary drug dissolution, absorption, metabolism and efficacy. Ultimately the use of the Calu-3 cell line provides a basic research tool that enables the development of safer and more effective inhaled therapeutics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23730924     DOI: 10.1517/17425247.2013.805743

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  23 in total

1.  Aerosolization Performance, Antitussive Effect and Local Toxicity of Naringenin-Hydroxypropyl-β-Cyclodextrin Inhalation Solution for Pulmonary Delivery.

Authors:  Minyi Guan; Xuan Zeng; Rui Shi; Yuying Zheng; Weiyang Fan; Weiwei Su
Journal:  AAPS PharmSciTech       Date:  2021-01-03       Impact factor: 3.246

2.  Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model.

Authors:  Guihong Chai; Heejun Park; Shihui Yu; Fanfan Zhou; Jian Li; Qingguo Xu; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-08-12       Impact factor: 5.875

3.  Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases.

Authors:  Hui Xin Ong; Daniela Traini; Giulia Ballerin; Lucy Morgan; Lachlan Buddle; Santo Scalia; Paul M Young
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

4.  Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil.

Authors:  Thi-Tram Nguyen; Eun-Jin Yi; Kyu-Mok Hwang; Cheol-Hee Cho; Chun-Woong Park; Ju-Young Kim; Yun-Seok Rhee; Eun-Seok Park
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

5.  In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.

Authors:  Jianting Chen; Maizbha U Ahmed; Chune Zhu; Shihui Yu; Weisan Pan; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-01-21       Impact factor: 5.875

6.  Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.

Authors:  Jin Huk Choi; Stephen C Schafer; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2015-01-20       Impact factor: 4.939

7.  Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir.

Authors:  Chiara Medaglia; Arnaud Charles-Antoine Zwygart; Paulo Jacob Silva; Samuel Constant; Song Huang; Francesco Stellacci; Caroline Tapparel
Journal:  Microorganisms       Date:  2021-06-01

8.  A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies.

Authors:  Laura Nižić Nodilo; Ivo Ugrina; Drago Špoljarić; Daniela Amidžić Klarić; Cvijeta Jakobušić Brala; Mirna Perkušić; Ivan Pepić; Jasmina Lovrić; Vesna Saršon; Maša Safundžić Kučuk; Dijana Zadravec; Livije Kalogjera; Anita Hafner
Journal:  Pharmaceutics       Date:  2021-05-26       Impact factor: 6.321

9.  Mechanism of mucosal permeability enhancement of CriticalSorb® (Solutol® HS15) investigated in vitro in cell cultures.

Authors:  Saif Shubber; Driton Vllasaliu; Cyril Rauch; Faron Jordan; Lisbeth Illum; Snjezana Stolnik
Journal:  Pharm Res       Date:  2014-09-05       Impact factor: 4.200

10.  Immunocompetent 3D model of human upper airway for disease modeling and in vitro drug evaluation.

Authors:  Helen Harrington; Paul Cato; Fabian Salazar; Malcolm Wilkinson; Alan Knox; John W Haycock; Felicity Rose; Jon W Aylott; Amir M Ghaemmaghami
Journal:  Mol Pharm       Date:  2014-03-24       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.